Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 3, 2002, Pages 257-264

  Mikaelsson, Marianne ^a   Oswaldsson, Ulla ^a  

^a BIOVITRUM AB   (Sweden)

Author keywords

Assay; Factor VIII; Hemophilia A; Pharmacokinetics; Recombinant

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CHROMOGENIC SUBSTRATE; PHOSPHOLIPID; REAGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBOCYTE FACTOR 3; DIAGNOSTIC AGENT; F8 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANALYTIC METHOD; ANTIGEN DETECTION; BLOOD CLOTTING TEST; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; HEMOPHILIA A; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; STANDARD; THROMBOCYTE COUNT; WORLD HEALTH ORGANIZATION; BLOOD; COMPARATIVE STUDY; METHODOLOGY;

BLOOD COAGULATION TESTS; CHROMOGENIC COMPOUNDS; COMPARATIVE STUDY; FACTOR VIII; HEMOPHILIA A; HUMAN; RECOMBINANT PROTEINS; HUMANS;

EID: 0036017369     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-32659     Document Type: Review

References (20)

1. Standardisation and assay
2. Discrepancies in potency assessment of recombinant FVIII concentrates
3. Recommendations for the assay of high-purity factor VIII concentrates
4. The design and analysis of half-life and recovery studies for factor VIII and factor IX
5. In vivo recovery with products of very high purity - Assay discrepancies
6. Pharmacokinetics of recombinant factor VIII (Recombinate) using one-stage clotting and chromogenic factor VIII assay
7. Comparison of activity and antigen measurements in a pharmacokinetic study of recombinant factor VIII SQ
8. Factor VIII concentrates and their clotting activity
9. Assay of factor VIII:C with chromogenic substrate
10. A simple and accurate microplate assay for determination of factor VIII activity
11. Influence of phospholipids on the assessment of factor VIII activity
12. Assay discrepancies in pharmacokinetic studies of recombinant factor VIII concentrates
13. One-stage factor VIII assays are affected by both type and amount of phospholipids
14. Newer concepts of blood coagulation
15. Biochemistry and physiology of blood coagulation
16. New insights into how blood clots: Implications for the use of aPTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy
17. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma
18. Comparison of r-VIII SQ with other factor VIII concentrates in the dilute thromboplastin test
19. Second generation, B-domain deleted recombinant factor VIII
20. Comparison of normal plasma and product-specific standards in the assessment of post-injection factor VIII activity